Technology Transfer News
XRnanotech, the latest PSI spin-off, is working on nanostructured X-ray optics that make the smallest things - the world of the nanometer - visible. Founded only a few months ago, the start-up already has numerous successes to its credit and is already in talks with its first customers and investors.
Roger Herger wrote his diploma thesis and doctoral dissertation on X-ray diffraction of complex metal oxides at the Swiss Light Source (SLS) synchrotron. At the end of June 2020, he founded the high-tech startup maXerial, together with two business partners. Their goal: to combine industrial X-ray technology with artificial intelligence. We trace his path from research to entrepreneur and show how cutting-edge PSI know-how and laboratory-based X-ray technology ideally complement each other to solve the challenges of the Swiss high-tech industry by means of data-driven materials development.
Even as a doctoral student at PSI, Agnese Carino wanted to put the findings of her research into practice and did not hesitate to present her business idea to the CEO of Medicoat AG, Philipp Gruner. She wanted to develop a novel coating for small implants, which accelerates the recovery of the patient, into a product. Supported by the Hightech Zentrum Aargau this was the starting point of the joint SNI project NanoCoat. Carino was awarded the Founder Fellowship by PSI for her business idea. This program supports the transition from promising research findings to marketable products. We are pleased that Dr. Carino is now working with Medicoat to advance the commercialization of this technology.
This year's Swiss Innovation Forum takes place from 17th - 19th November as a 3-day virtual conference. Under the motto "It's time to innovate - NOW" the focus is on creativity, innovation and technology. Which technological trends will conquer the market? And what impact will Covid-19 have on future innovations? These and other questions will be addressed at this year's Swiss Innovation Forum.
PSI will be there - visit us at our virtual booth and find out more about how the technology transfer centre ANAXAM uses state-of-the-art material analysis to support both industry and SMEs in optimising production methods and processes, thus creating the basis for innovations.
With its extraordinary X-ray optics, XRNanotech GmbH, PSI's latest spin-off, was able to convince the jury of the "Business Incubation Centre (BIC) of CERN Technologies" programme of Park Innovaare and prevail over the other finalists. As the winner of this programme, the start-up will receive CHF 50,000 as well as further support from the University of Applied Sciences Northwestern Switzerland, CERN and PSI.
Araris, one of PSIs youngest spin-offs, today announced that they have successfully closed a CHF 15.2M seed round with a group of previous and new investors. The funds raised will allow the further development of the ADC linker technology licensed out by PSI and hopefully identify potent drug candidates.
Dr. Philipp Spycher, CEO of Araris Biotech AG began his entrepreneurial endeavors with the PSI Founder Fellowship that helped kick-start his ideas of building a business around the technology that he helped to develop at PSI.
PSI applauds this development and looks forward to a bright future for Araris.
Wednesday, November 11, 2020, from 13:30 to 18:00
Empa, Überlandstrasse 129, 8600 Dübendorf (Participation possible on site OR via Zoom)
Online registration: www.empa-akademie.ch/technology
The conference series aims at informing our industry and business partners about pressing issues of practical relevance. Speakers representing CSEM, Empa, PSI and industry will cover a well-balanced and practice-oriented overview of the latest technologies. The event also provides a platform for knowledge sharing and exchange of experiences, allowing the identification of potential cooperation and further innovation.
Several months have now passed since the new technology transfer centre "ANAXAM" was founded. Under the management of Dr. Christian Grünzweig and in close cooperation with PSI, ANAXAM is on the road to success for industry - time for a brief review.
Debio 1124 - a compound developed at PSI and out-licensed to the Swiss company Debiopharm - is being tested in a clinical phase I study in patients with small cell lung cancer, as Debiopharm has published in a press release. The peptide binds highly specifically to proteins found on tumour cells in this type of cancer. If Debio 1124 is coupled to a nuclide, it can be used both to detect the tumour with imaging procedures and therapeutically to destroy the tumour cells bound in this way.